387 related articles for article (PubMed ID: 15063962)
21. [Role of the steroids, SHBG, IGF-1, IGF BP-3 and growth hormone in glucose metabolism disorders during long-term treatment with low doses of glucocorticoids].
Vondra K; Hampl R; Nĕmcová D; Hill M; Hoza J; Kot'átková A; Stárka L; Vrbíková J; Zamrazil V
Cas Lek Cesk; 2002 Feb; 141(3):89-95. PubMed ID: 11925670
[TBL] [Abstract][Full Text] [Related]
22. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome.
Khorram O; Helliwell JP; Katz S; Bonpane CM; Jaramillo L
Fertil Steril; 2006 May; 85(5):1448-51. PubMed ID: 16579997
[TBL] [Abstract][Full Text] [Related]
23. [Can hormonal contraceptives affect plasma levels of IGF-1 and IGFBP-1 in slim women with polycystic ovary syndrome?].
Sindelka G; Cibula D; Fanta M; Kasalová Z; Justová V; Lacinová Z; Skrha J
Cas Lek Cesk; 2001 Aug; 140(15):469-72. PubMed ID: 11569168
[TBL] [Abstract][Full Text] [Related]
24. Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome.
Seibel SA; Chou KH; Capp E; Spritzer PM; von Eye Corleta H
Eur J Obstet Gynecol Reprod Biol; 2008 May; 138(1):122-4. PubMed ID: 17350746
[No Abstract] [Full Text] [Related]
25. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
Tan BK; Heutling D; Chen J; Farhatullah S; Adya R; Keay SD; Kennedy CR; Lehnert H; Randeva HS
Diabetes; 2008 Jun; 57(6):1501-7. PubMed ID: 18375437
[TBL] [Abstract][Full Text] [Related]
26. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Alexandraki K; Piperi C; Aessopos A; Paterakis T; Katsikis I; Panidis D
Metabolism; 2007 Jan; 56(1):129-34. PubMed ID: 17161235
[TBL] [Abstract][Full Text] [Related]
27. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance.
Nawrocka J; Starczewski A
Gynecol Endocrinol; 2007 Apr; 23(4):231-7. PubMed ID: 17505944
[TBL] [Abstract][Full Text] [Related]
28. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
29. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
30. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
31. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Piperi C; Kalofoutis A; Creatsas G
Clin Endocrinol (Oxf); 2005 Jan; 62(1):37-43. PubMed ID: 15638868
[TBL] [Abstract][Full Text] [Related]
32. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome.
De Leo V; La Marca A; Orvieto R; Morgante G
J Clin Endocrinol Metab; 2000 Apr; 85(4):1598-600. PubMed ID: 10770203
[TBL] [Abstract][Full Text] [Related]
33. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
Wang A; Li M; Lu C
Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
[TBL] [Abstract][Full Text] [Related]
34. Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.
Berker B; Emral R; Demirel C; Corapcioglu D; Unlu C; Kose K
Gynecol Endocrinol; 2004 Sep; 19(3):125-33. PubMed ID: 15697073
[TBL] [Abstract][Full Text] [Related]
35. The effects of metformin and diet on plasma testosterone and leptin levels in obese men.
Ozata M; Oktenli C; Bingol N; Ozdemir IC
Obes Res; 2001 Nov; 9(11):662-7. PubMed ID: 11707532
[TBL] [Abstract][Full Text] [Related]
36. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y
Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298
[TBL] [Abstract][Full Text] [Related]
37. [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
Vrbíková J; Hill M; Stárka L; Cibula D; Snajderová M; Sulcová J; Vondra K; Bendlová B
Cas Lek Cesk; 2001 Nov; 140(22):688-94. PubMed ID: 11789058
[TBL] [Abstract][Full Text] [Related]
38. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
[TBL] [Abstract][Full Text] [Related]
39. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
40. [The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome].
Liang X; Zhuang G; Fan Q
Zhonghua Yi Xue Za Zhi; 1997 Apr; 77(4):266-9. PubMed ID: 9596926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
